Abstract
Cognitive Impairment (CI) in Parkinson’s disease (PD) is one of the important non-motor symptoms that can begin even before the motor symptoms manifest. As the disease progresses into advance stages, however, virtually all patients suffer from cognitive decline. PD Patients hypothetically progress across PD with no CI (PD-NC), Mild Cognitive Impairment (PD-MCI), and PD dementia (PDD). The CI symptoms in PD are linked to different brain regions including dysfunctional subcortical regions and poorly elucidated neural pathways. However, it is still unknown how functional dysregulation in some brain regions correlates to CI progression in PD. Recently, rsfMRI has been shown to be a promising neuroimaging technique that can enable discovery of CI biomarkers in PD. Here, we investigated the differences in the clinical measures and the resting-state Functional Connectivity (FC) of three CI subtypes of PD. We included a total of 114 participants, (26 PD-NC, 32 PD-MCI, 31 PDD, and 26 Healthy Controls (HC), and performed intra- and inter-network FC analysis together with comprehensive clinical cognitive assessment. Our results showed the importance of several neural networks including Default Mode Network (DMN), Frontoparietal Network (FPN), Dorsal Attention Network (DAN), and Visual Network (VN) and their inter-intra network FC distinguishing between PD-MCI and PDD. Additionally, our results showed the importance of Sensory Motor Network (SMN), VN, DMN, and Salience Network (SN) in the discriminating PD-NC from PDD. Finally, in comparison to HC, we found DMN, FPN, VN, and SN as important networks for further differential diagnosis of CI subtypes of PD. We propose that resting state networks can be used in stratifying the CI subtypes of PD patients in the clinic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by a grant to Suleyman Yildirim from the Scientific and Technological Research Council of Turkiye (TUBITAK) (grant no. 1003-315S301)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ISTANBUL MEDIPOL UNIVERSITY NON-INTERVENTIONAL CLINICAL STUDY ETHICS COMMITTEE approved this study (Approval no.10840098-604.01.01-E.3958, 18/11/2015).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors